Navigation Links
MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Date:12/4/2008

p>

About AFRESA

Afresa is an ultra rapid acting inhaled insulin product that has completed Phase 3 trials. The pharmacokinetic profile of Afresa sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive Afresa particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the promise for AFRESA, next steps in the Company's clinical trial program, plans and timing for the subm
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MannKind Announces New $350 Million Credit Facility
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports Third Quarter Financial Results
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind to Present at the Cowen and Company Healthcare Conference
6. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
7. MannKind Corporation to Host Webcast Analyst Day September 16, 2008
8. MannKind Corporation Reports Third Quarter Financial Results
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. ... medical implants -- artificial valves, hip replacements, surgical mesh and ... before or after their approval by the U.S. Food and ... conducted by prominent nonprofit groups and published online Sept. 29 ... for inadequate medical device testing on lax oversight by the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Houstonians seeking ... a place to visit on the Internet. Paul ... Houston’s most respected cosmetic surgeons, has launched a new ... the benefits of Botox Cosmetic services. The ... , According to the new website, Botox Cosmetic ...
(Date:9/30/2014)... September 30, 2014 Neuromuscular and ... throughout the United States and worldwide. It is ... are diagnosed each year, adding to the more ... disease. Approximately 400,000 people in the US are ... Add to these statistics the 2.4 percent of ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Farnoosh is now offering gum depigmentation treatments for dark ... but they can make people feel extremely self-conscious about ... treat discolored or dark gums. “I am one of ... lightening , and I have treated celebrities, business leaders, ...
(Date:9/30/2014)... Herceptin is the best drug treatment for a type ... standard of care for that type of tumor, according ... HER2-positive breast cancers tend to be more aggressive than ... Clinic. For the study, more than 8,300 patients ... (lapatinib) in addition to standard chemotherapy. After 4.5 ...
Breaking Medicine News(10 mins):Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2
... Researchers at the Food Technology Plant Special Research Centre ... celiac disease// otherwise called as gluten sensitive enteropathy. This ... known to have enhanced nutritive value and increased shelf ... of gluten, forcing sufferers to follow a strictly gluten-free ...
... plenty of good reasons, the term “trans fat” leaves ... Typically, trans fatty acids are bad for health, but// ... have coaxed out significant health benefits by juggling the ... professor of food science, and graduate student Vishal Jain ...
... today urged Australians to spare a thought this week for ... time of year for most people means joyful gatherings with ... and despair,' Dr Yong said. ,'The social circuit, ... can cause depression for those who are socially isolated. ...
... obstinate, as scientists have discovered, as they portray a ... extremely// difficult to annihilate. In fact radiation could even ... from the University of California, Los Angeles, who are ... cells that get radiation resistant and render breast cancer ...
... producing cane sugar with lower glycaemic index (GI) that it ... ranking system for carbohydrates based on their immediate effect on ... risk of diabetes because they trigger rapid increases in blood ... ,The sugar, developed by firm 'Horizon Science of ...
... 'DNA-diets', advertised extensively on the internet, making tall claims of ... ,A study, spearheaded by researchers at the Economic and Social ... University of Exeter, is the first study of its kind ... diets are also called 'nutrigenomic' diets that are customized diet ...
Cached Medicine News:Health News:Gluten Free Bread: Boon for Celiac Disease 2Health News:Healthy Potato Chips: A Trans Fat Oil With Health Benefits 2
(Date:9/30/2014)... 30, 2014  Come fall, many children, teenagers, and ... they want to be for Halloween. And, a number ... decorative contact lenses bought without a prescription. ... people purchase and wear contact lenses without a prescription. ... ® consumer survey, 17 percent of Americans have ...
(Date:9/30/2014)... Sept. 30, 2014 Established and new ... distributors to help penetrate the growing Eastern European ... for a sales team and regional/local offices, reducing ... This is a crucial advantage as medical technology ... environment. New analysis from Frost & ...
(Date:9/30/2014)... -- China,s regulatory ... The country,s new leaders have recognized that the regulations ... far from perfect along with rapid population growth and ... council issued the latest "Regulations for the Supervision and ... it has come into force as June 1, 2014. ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 2Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 3Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 5
... announced today that CH live ... Measures (i.e. eMeasures).  CredenceHealth is the first real-time Clinical ... " CCHIT is pleased to be testing ... to offer these products to providers who wish to ...
... STEWARTVILLE, Minn., Jan. 12, 2011 Rochester Medical Corporation ... reached an agreement with Fornix N.V. to purchase from ... supplies distribution company located in Beuningen, The Netherlands.  Laprolan ... the Dutch market and had unaudited revenues of approximately ...
Cached Medicine Technology:CredenceHealth's CHlive Meaningful Use Certified (ONC-ATCB 2011/2012 Certification) 2CredenceHealth's CHlive Meaningful Use Certified (ONC-ATCB 2011/2012 Certification) 3Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V. 2Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V. 3
Ergonomic design and intuitive operations. Unique DOX digital SpO2 technology improves performance, even under the most challenging clinical conditions....
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
Medicine Products: